Statin discontinuation in older adults lacks robust randomized evidence despite widespread long-term use for primary prevention. The clinical value of continuing statins beyond age 75-80 remains uncertain, requiring individualized assessment rather than automatic continuation of therapy initiated decades earlier.
Key Points
- Randomized evidence for statin benefit in older primary prevention patients is remarkably limited
- Continuing statins in late-life requires reassessment of individual risk-benefit calculus
- Default continuation practices may not reflect current evidence or changing physiology
Longevity Analysis
Pharmacological interventions initiated in middle age are often continued without periodic reassessment of whether they remain appropriate as physiological capacity, disease trajectory, and life expectancy shift. This work addresses a critical gap: the evidence base for maintaining preventive therapies in advanced age is thinner than clinical practice patterns suggest. Effective health optimization requires decoding whether a medication's original rationale persists, particularly when burden accumulates from polypharmacy and when individual vulnerability to adverse effects increases. The default assumption that successful early intervention warrants indefinite continuation—rather than strategic reassessment—may represent a form of therapeutic inertia that diminishes net benefit over the lifespan.
Original published by The Lancet Healthy Longevity, by Shefa Arya Nezhad, Parvaneh Rastgou, Michael G Nanna.